Prothena (PRTA) vs Tectonic Therapeutic (TECX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Tectonic Therapeutic (TECX) has outperformed Prothena (PRTA) over the past year, gaining 52.3% versus a loss of 16.6%. Over five years, TECX leads with a -67.4% price change compared with -86.6% for PRTA. Tectonic Therapeutic is the larger company by market cap ($444.0 million vs $435.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PRTA | TECX |
|---|---|---|
| Share price | $8.48 | $22.71 |
| Market cap | $435.34M | $443.97M |
| 1-day change | +5.74% | +1.34% |
| YTD return | -11.20% | +8.87% |
| 1-year return | -16.62% | +52.31% |
| 5-year return | -86.64% | -67.37% |
| EPS (TTM) | $-0.87 | $-4.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $11.80 | $39.53 |
| 52-week low | $7.73 | $15.32 |
| Distance from 52-week high | -28.14% | -42.55% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +152.36% | +237.43% |
| Average volume | 478.70K | 219.12K |
| Shares outstanding | 51.34M | 19.55M |
| Employees | 67 | 60 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TECX has outperformed PRTA by 68.9 percentage points over the past year.
About Prothena
PRTA stock →Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies.
Healthcare · Biotechnology · 67 employees
About Tectonic Therapeutic
TECX stock →Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines.
Healthcare · Biotechnology · 60 employees
PRTA vs TECX FAQ
Which is bigger, Prothena or Tectonic Therapeutic?
Tectonic Therapeutic (TECX) is larger, with a market capitalization of $443.97M compared with $435.34M for Prothena (PRTA).
Which stock has performed better over the past year, PRTA or TECX?
TECX returned +52.31% over the past 12 months, compared with -16.62% for PRTA (price return, excluding dividends). Past performance does not predict future results.
Are Prothena and Tectonic Therapeutic in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.